Status:

WITHDRAWN

Digital Diabetes Prevention Program Study

Lead Sponsor:

Hospital for Special Surgery, New York

Conditions:

PreDiabetes

Eligibility:

All Genders

18-64 years

Phase:

NA

Brief Summary

The aim of this study is to determine if completion of the Diabetes Prevention Program (DPP) via the Transform 10 website can significantly decrease hemoglobin A1c (HbA1c) levels and Body Mass Index (...

Detailed Description

Glycemic, or blood sugar, control is an important factor associated with improved outcomes for patients after surgery. With one in three adults in the United States living with prediabetes, poor glyce...

Eligibility Criteria

Inclusion

  • Planned primary total hip arthroplasty for the indication of osteoarthritis at facility
  • Age 18 - 64
  • Overweight (BMI 25+ or 22+ if Asian)
  • HbA1c 5.7%-6.4%
  • Predicted ability to walk following procedure
  • English or Spanish speaking
  • Able to provide informed consent
  • Willing to accept a random assignment
  • Readiness for change
  • ASA 1 or 2

Exclusion

  • Not meeting all inclusion criteria
  • Diagnosed with Type I or II diabetes
  • Diagnosed with congestive heart failure, coronary artery disease, chronic obstructive pulmonary disease, pulmonary hypertension
  • Diagnosed with dementia or probable Alzheimer's disease
  • Taking oral hypoglycemic agents other than Metformin
  • Participating in a concurrent weight management program outside of HSS current protocol
  • Unable to engage in walking as physical activity post-procedure
  • Had bariatric surgery within the past 3 years or planning surgery within the next 12 months
  • Anti-obesity or diabetes therapy within the preceding 4 months
  • Any mental health condition, including eating disorders or alcohol/substance use, which would preclude full participation
  • Self-report as currently pregnant or within 6 weeks of having given birth (or planning to become pregnant in the next 12 months)
  • Unstable cardiac disease (i.e. heart attack/failure or stroke in the last 6 months, or currently in cardiac rehabilitation)
  • On dialysis or an active organ transplant list
  • Chronic kidney disease
  • Untreated thyroid disease
  • Cancer within the last 5 years unless skin cancer (i.e. currently or within the last 5 years in chemotherapy or radiation treatment)
  • Unwilling to accept random assignment

Key Trial Info

Start Date :

January 24 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 4 2024

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT06137963

Start Date

January 24 2024

End Date

April 4 2024

Last Update

December 27 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital for Special Surgery

New York, New York, United States, 10021